Davis T E, Kahan L, Tormey D C, Larson F C, Anderson S A, Crowley J J, Carey R N
Cancer Res. 1981 Mar;41(3):1110-3.
The activity of an isoenzyme of alkaline phosphatase (FHAP) was measured in serum samples obtained from 1692 individual subjects. The median FHAP concentration in patients with untreated or recurrent cancer (2.73 IU/liter) was two-fold higher than in hospitalized control patients with illnesses other than cancer (1.17 IU/liter) and three-fold higher than in healthy control subjects (0.93 IU/liter). Among patients with either breast or colorectal cancer who were clinically disease free following their initial therapy, the median FHAP concentration (1.54 IU/liter) was intermediate between the median FHAP concentration in patients with untreated or recurrent cancer and that of healthy control subjects. In order to illustrate the potential clinical application of FHAP as a diagnostic cancer marker, we have selected a serum FHAP concentration of 2.22 IU/liter as a reference value above which only 3% of healthy control subjects would have a "positive" test. Utilizing this reference value, 58% of the patients in the present study with untreated or recurrent cancer would have a positive FHAP test, whereas only 11%, of hospitalized patients with illnesses other than cancer would have a positive test. These data suggest that FHAP may be equivalent to the carcinoembryonic antigen as a diagnostic cancer marker.
在从1692名个体受试者采集的血清样本中检测了碱性磷酸酶同工酶（FHAP）的活性。未经治疗或复发癌症患者的FHAP浓度中位数（2.73国际单位/升）比非癌症疾病的住院对照患者（1.17国际单位/升）高两倍，比健康对照受试者（0.93国际单位/升）高三倍。在初始治疗后临床无疾病的乳腺癌或结直肠癌患者中，FHAP浓度中位数（1.54国际单位/升）介于未经治疗或复发癌症患者与健康对照受试者的FHAP浓度中位数之间。为了说明FHAP作为诊断癌症标志物的潜在临床应用，我们选择血清FHAP浓度2.22国际单位/升作为参考值，高于该值只有3%的健康对照受试者会有“阳性”检测结果。利用该参考值，本研究中58%未经治疗或复发癌症的患者FHAP检测会呈阳性，而只有11%非癌症疾病的住院患者检测会呈阳性。这些数据表明，FHAP作为诊断癌症标志物可能与癌胚抗原相当。
